A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study

Investigational New Drugs

Volumn 22, Issue 3, 2004, Pages 335-341

  Whitehead, Robert P ^a   Benedetti, Jacqueline K ^b   Abbruzzese, James L ^c   Ardalan, Bach ^d   Goodwin, J Wendall ^e   Balcerzak, Stanley P ^f   Samlowski, Wolfram E ^g   Lenz, Heinz Josef ^h   Macdonald, John S ⁱ  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Ozarks Reg Clin Oncology Program   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

5 FU; Leucovorin; PALA; Pancreas cancer; Phase II

Indexed keywords

FLUOROURACIL; FOLINIC ACID; SPARFOSIC ACID;

ADULT; ADVANCED CANCER; AGED; ANGINA PECTORIS; ARTICLE; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CROSSOVER PROCEDURE; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE ISCHEMIA; HISTOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LETHARGY; LYMPHOCYTOPENIA; MALAISE; MALE; METASTASIS; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN ULCER; SURVIVAL RATE; URTICARIA; VERTIGO; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHONOACETIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3543001624     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000026261.76197.54     Document Type: Article

References (39)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics 2003. CA A Cancer Journal for Clinicians 53: 5-26, 2003
2. Cornell GN, Cahow CE, Frey C, McSherry C, Beal JM: Clinical experience with 5-fluorouracil (NSC-19 893) in the treatment of malignant disease. Cancer Chemother Rep 9: 23-30, 1960
3. Hurley JD, Ellison EH: Treatment of advanced cancer with 5-fluorouracil. Annals Surg 152: 568-582, 1960
4. Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Seminars in Oncology 23: 220-228, 1996
5. Martin DS, Kemeny NE: Modulation of fluorouracil by N-(phosphonacetyl)-L- asparate: A review. Seminars in Oncology 19: (2, Suppl 3), 49-55, 1992
6. Moran RG, Scanlon KL: Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Research 51: 4618-4623, 1991
7. Grem JL, Hoth D, Hamilton MJ, King SA, Leyland-Jones B: An overview of the current status and future directions of clinical trials of 5-fluorouracil and folinic acid. Cancer Treatment Reports 71: 1249-1264, 1987
8. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Journal of Clinical Oncology 10: 896-903, 1992
9. Ullman B, Lee M, Martin DW Jr, Santi DV: Cytotoxicity of 5-fluoro-2′-deoxyuridine: Requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 75(2): 980-983, 1978
10. Evans RM, Laskin JD, Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288-3295, 1981
11. Houghton JA, Maroda SJ Jr, Philips JO, Houghton PJ: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatves in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41: 144-149, 1981
12. Meropol NJ, Creaven PJ, Petrelli NJ: Metastatic colorectal cancer: Advances in biochemical modulation and new drug development. Seminars in Oncology 22(5): 509-524, 1995
13. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bulowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JS, Benedetto P, Wooley PV, Nauta R, Weaver DW, Leichman LP for the Gastrointestinal Tumor Study Group: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989
14. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG: Fluorouracil and high-dose leucovorin in previously untreated patents with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 9: 2128-2133, 1991
15. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1418, 1989
16. Crown J, Casper ES, Botet J, Murray P, Kelsen DP: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9: 1682-1686, 1991
17. Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B: Biochemistry and clinical activity of N-(Phosphonacetyl)-L-aspartate: A review. Cancer Research 48: 4441-4454, 1988
18. Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG, Sorensen JM, Chen AP, Goldstein L, Jordan E, Setser A, Goldspiel B, DeCarvalho M, Allegra CJ: A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(Phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. Cancer Research 53: 4828-4836, 1993
19. Ardalan B, Glazer RI, Kensler TW, Jayaram HN, Van Pham T, Macdonald JS, Cooney DA: Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L- aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma. Biochem Pharmacol 30: 2045-2049, 1981
20. Spiegelman S, Sawyer R, Nayak R, Ritzi E, Stolfi R, Martin D: Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci USA 77: 4966-4970, 1980
21. Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, Young CW: Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance. Cancer Res 43: 2317-2321, 1983
22. Johnson RK, Clement JJ, Howard WS: Treatment of murine tumors with 5-fluorouracil in combination with de novo pyrimidine synthesis inhibitors PALA or pyrazofurin. Proceedings AACR 21: 292, 1980 (abstract)
23. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short-term infusion of high dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6: 1053-1058, 1988
24. Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ: Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 29: 305-308, 1992
25. Tian E, Ardalan B, Benedetto P, Feun L, Morrell L, Waldman S, Hurley J, Savaraj N, Richman S, Livingstone A, Anac S: A phase II study of short term protracted infusion of high dose 5-fluorouracil (5-FU) with !eucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in pancreatic carcinoma. Proc Am Soc Clin Oncol 11: 184, 1992 (abstract)
26. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253, 1992
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
28. Green SI, and Dahlberg S: Planned versus attained design in Phase II clinical trials. Statistics in Medicine 11: 853-862, 1992
29. Burris III HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997
30. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2′,2′- difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994
31. Morrell LM, Bach A, Richman SP, Goodman P, Fleming TR, MacDonald JS: A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5 fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study. Cancer 67: 363-366, 1991
32. Harstrick A, Kohne-Wompner CH, Preusser P, Hiddemann W, Wilke H, Strumberg D, Papageorgiou E, Schmoll HJ: A phase II study of the combination of PALA, methotrexate and 5-FU in advanced pancreatic carcinoma. Proceed ASCO 12: 219, 1993 (abstract)
33. Redei I, Green F, Hoffman JP, Weiner LM, Scher R, O'Dwyer PJ: Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer. Invest New Drugs 12: 319-321, 1994
34. Bolli E, Saccomanno S, Mondini G, Aschele C, Guglielmi A, Ligas B, Connio M, Mori A, Rosso R, Sobrero A, Tixi L, Pugliese V: On behalf of the GLISP (Gruppo Ligure Studio Pancreas): 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas). Cancer Chemother Pharmacol 35: 339-342, 1995
35. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B: Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70: 2073-2076, 1992
36. Moore MJ, Erichman C, Kaizer L, Fine S: A phase II study of 5-fluorouracil, leucovorin and interferon alpha in advanced pancreatic cancer. Anticancer Drugs 4: 555-557, 1993
37. Bernhard H, Jager-Arand E, Bernhard G, Heike M, Klein O, Riemann JF, Meyer zum Buschenfelde KH, Dippold W, Knuth A: Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: Results of a phase II trial. British Journal Cancer 71: 102-105, 1995
38. Scheithauer W, Pfeffel F, Kornek G, Marczell A, Wiltschke C, Funovics J: A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 70: 1864-1866, 1992
39. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20: 160-164, 2002